Fundraising Fox
Transition Bio
Cambridge, US · Founded 2020 · Delaware corporation · 5 known investors
Find your way into Transition Bio
Sign up to see every warm intro you have to Transition Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Transition Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Founders & leadership
Transition Bio was founded in 2020 by Tuomas Knowles, Samuel Cohen, and G. Kelly Martin.
Board
Investors · 5
How we know: the company's own site · a partner's Signal profile · funding news · citybiz.co · Not right? Tell us
How we know: Lifeforce Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Magnetic Ventures's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$58.4M disclosed across 3 rounds · 2022–2024
▶$13.3MraisedOct 2024 · 8 investors · BiotechnologyRule 506(b)
- Tuomas KnowlesDirector
- Kathy YiDirector
- Robert WeeksDirector
- George MartinExecutive Officer, Director
- Al SandrockDirector
- Stephanie TorruellaExecutive Officer
- Samuel CohenDirector
- Preet MakkarExecutive Officer
- Paxton MajorDirector
- Offering amount
- $21.3M
- Amount sold
- $13.3M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6MraisedJan 2024 · 5 investors · BiotechnologyRule 506(b)
- Samuel CohenDirector
- Connor McDermottDirector
- Tuomas KnowlesExecutive Officer, Director
- George MartinExecutive Officer, Director
- Preet MakkarExecutive Officer
- Kathy YiDirector
- Stephanie TorruellaExecutive Officer
- Al SandrockDirector
- Offering amount
- $15M
- Amount sold
- $6M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$39.1MraisedMar 2023 · 22 investors · BiotechnologyRule 506(b)
- Kathy YiDirector
- Samuel CohenDirector
- George K. MartinDirector
- Martin KulanderExecutive Officer
- Connor McDermottDirector
- Tuomas KnowlesExecutive Officer
- Gregory L. MillerExecutive Officer, Director
- Al SandrockDirector
- Offering amount
- $50M
- Amount sold
- $39.1M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Transition Bio do?
- Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
- Who founded Transition Bio?
- Transition Bio was founded by Tuomas Knowles, Samuel Cohen, G. Kelly Martin in 2020.
- Who are Transition Bio's investors?
- Transition Bio's investors include Northpond Ventures, Lifeforce Capital, Magnetic Ventures, Taiho Ventures, LLC, Dolby Family Ventures.
- How much funding has Transition Bio raised?
- Transition Bio has disclosed $58.4M raised across 3 rounds.
- Where is Transition Bio headquartered?
- Transition Bio is headquartered in Cambridge, US.